- Trial phase
- Phase 1 completed; Phase 2 ready
- Time to market
- Minimum 3-4 years, assuming positive Phase 2 data drives Phase 3 and potential accelerated approval via FDA-recognized surrogate endpoint (total kidney volume)
- Why 6/10
- The next hard, dated catalyst for SCY-770 is the Phase 2 proof-of-concept early efficacy readout expected in H2 2027 (~8-14 months out). The Phase 2 study initiation (imminent, Q4 2026) is an operational milestone, not a binary catalyst. SCY-770 is a major value driver but SCYX also has SCY-247 (antifungal with BARDA funding) and BREXAFEMME licensing revenue, so the company is not a single-asset binary.
Watch for the Phase 2 proof-of-concept study initiation in Q4 2026 (imminent) and, more importantly, the early efficacy readout on total kidney volume expected in the second half of 2027. SCY-770 must demonstrate a meaningful reduction in kidney growth versus placebo to justify the valuation implied by analyst targets (~$36 mean). Until then, the stock is driven by SCY-247 antifungal progress and the $214M BARDA contract, SCY-770 remains a high-risk/high-reward pipeline component.
Price Chart
Executive Summary
SCY-770 is a first-in-class oral direct AMPK activator being developed by SCYNEXIS (NASDAQ: SCYX) for Autosomal Dominant Polycystic Kidney Disease (ADPKD), a rare genetic kidney disorder. Acquired from Poxel in March 2026 for $8M upfront (up to $196M total), the drug completed a positive Phase 1 study in October 2026 showing favorable safety/tolerability at higher doses in 25 healthy volunteers. A Phase 2 proof-of-concept study is expected to launch in Q4 2026 with an early efficacy readout in H2 2027. SCY-770 has FDA Orphan Drug Designation and targets a market where the only approved disease-modifying therapy is Tolvaptan (Jynarque). The drug represents a major pipeline expansion for SCYX beyond its antifungal platform, but remains early-stage with no efficacy data in patients yet.
How It Works
SCY-770 activates AMPK, a protein that acts as the cell's energy master switch. In ADPKD, abnormal cell growth causes fluid-filled cysts to form and enlarge in the kidneys. By turning on AMPK, SCY-770 aims to normalize cell energy use and suppress the signals driving cyst growth, potentially slowing or halting disease progression. It is taken orally as a pill.
Trial Status
Phase 1 completed October 2026: 25 healthy participants dosed at 500mg single dose (fed/fasted), 750mg once daily x7 days, or 500mg twice daily x7 days vs placebo. Well tolerated with favorable safety profile at all doses. Phase 2 proof-of-concept study in ADPKD patients expected to initiate in Q4 2026, with early efficacy readout anticipated H2 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 proof-of-concept study initiation (imminent, Q4 2026)
- Early efficacy readout from Phase 2 (H2 2027)
- Q3 2026 earnings report (November 11, 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Scynexis Press Release SCYX ·Originating report